Alnylam Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BIT:1ALNY Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
16 Apr 25	Sell€7,379	Colleen Reitan	Individual	36	€204.96
03 Mar 25	Sell€293,566	Jeffrey Poulton	Individual	1,264	€236.61
03 Mar 25	Sell€171,869	Kevin Fitzgerald	Individual	740	€236.61
03 Mar 25	Sell€180,235	Pushkal Garg	Individual	776	€236.61
03 Mar 25	Sell€109,389	Tolga Tanguler	Individual	471	€235.65
03 Mar 25	Sell€900,459	Yvonne Greenstreet	Individual	3,877	€236.61
28 Feb 25	Sell€115,215	Kevin Fitzgerald	Individual	496	€234.61
14 Feb 25	Sell€161,083	Kevin Fitzgerald	Individual	663	€252.16
14 Feb 25	Sell€379,205	Pushkal Garg	Individual	1,561	€252.16
14 Feb 25	Sell€234,906	Jeffrey Poulton	Individual	967	€252.16
14 Feb 25	Sell€294,669	Yvonne Greenstreet	Individual	1,213	€252.16
26 Nov 24	Sell€352,095	Kevin Fitzgerald	Individual	1,469	€240.92
26 Nov 24	Sell€403,148	Jeffrey Poulton	Individual	1,682	€240.92
26 Nov 24	Sell€352,095	Tolga Tanguler	Individual	1,469	€240.92
26 Nov 24	Sell€403,148	Pushkal Garg	Individual	1,682	€240.92
26 Nov 24	Sell€1,250,909	Yvonne Greenstreet	Individual	5,219	€240.92
17 Oct 24	Buy€9,570	Colleen Reitan	Individual	36	€279.52
25 Jun 24	Sell€346,389	Jeffrey Poulton	Individual	1,605	€219.74
25 Jun 24	Sell€453,858	Pushkal Garg	Individual	2,103	€219.74
25 Jun 24	Sell€258,550	Kevin Fitzgerald	Individual	1,198	€219.74
25 Jun 24	Sell€346,389	Tolga Tanguler	Individual	1,605	€219.74
25 Jun 24	Sell€1,791,497	Yvonne Greenstreet	Individual	8,301	€219.74

Insider Trading Volume

Insider Buying: 1ALNY insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1ALNY?
Owner Type	Number of Shares	Ownership Percentage
State or Government	58,955	0.0445%
Individual Insiders	429,794	0.324%
Public Companies	4,444,445	3.35%
Institutions	127,665,355	96.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 81.68% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
18.6%	Capital Research and Management Company	24,193,584	€6.2b	-4.55%	0.3%
11.5%	FMR LLC	14,970,183	€3.8b	13.5%	0.23%
10%	The Vanguard Group, Inc.	13,056,605	€3.3b	2.54%	0.05%
7.33%	BlackRock, Inc.	9,551,239	€2.4b	-3.38%	0.04%
6.08%	T. Rowe Price Group, Inc.	7,923,313	€2.0b	2.85%	0.19%
3.41%	Regeneron Pharmaceuticals, Inc.	4,444,445	€1.1b	0%	no data
2.81%	Baillie Gifford & Co.	3,657,607	€936.0m	-9.47%	0.43%
2.58%	State Street Global Advisors, Inc.	3,366,583	€861.5m	-1.64%	0.03%
2.57%	Dodge & Cox	3,351,762	€857.7m	-5.32%	0.29%
2%	Wellington Management Group LLP	2,610,986	€668.1m	-37.8%	0.11%
1.88%	Norges Bank Investment Management	2,456,082	€628.5m	0%	0.05%
1.78%	Geode Capital Management, LLC	2,322,834	€594.4m	5.26%	0.04%
1.54%	JP Morgan Asset Management	2,006,518	€513.5m	0.92%	0.06%
1.35%	American Century Investment Management Inc	1,760,435	€450.5m	9.75%	0.22%
1.25%	Orbis Investment Management (U.S.), L.P.	1,634,923	€418.4m	0%	2.51%
1.13%	Orbis Investment Management Limited	1,472,802	€376.9m	0%	1.21%
0.91%	Winslow Capital Management, LLC	1,187,178	€303.8m	16.3%	1.13%
0.76%	UBS Asset Management AG	989,236	€253.1m	-1.13%	0.02%
0.71%	Bank of America Corporation, Asset Management Arm	928,874	€237.7m	206%	0.07%
0.68%	Legal & General Investment Management Limited	881,111	€225.5m	6.3%	0.05%
0.66%	Northern Trust Global Investments	865,020	€221.4m	-1.57%	0.03%
0.63%	Invesco Ltd.	816,198	€208.9m	78.3%	0.06%
0.59%	Bellevue Asset Management AG	768,147	€196.6m	-0.28%	3.1%
0.56%	AQR Capital Management, LLC	736,011	€188.3m	0%	0.25%
0.43%	Charles Schwab Investment Management, Inc.	554,606	€141.9m	7.91%	0.02%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 20:03
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 61 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ishan Majumdar	Baptista Research
Huidong Wang	Barclays
Emily Bodnar	Berenberg